Evidence map›Paper›PMID 25425692›Full record

Trial reportHaematologica2015

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.

Jaap J Zwaginga, Bronno van der Holt, Peter A Te Boekhorst, Bart J Biemond, Mark-David Levin, René van der Griend, Anneke Brand, Sonja Zweegman, Hans F M Pruijt, Vera M J Novotny and 17 more

Open access · goldAbstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 18 institutions in 3 countries.

Jaap J ZwagingaDept. of Immunohematology and Blood Transfusion, Leiden University Medical Center and the Jon J van Rood Center for Clinical Transfusion Research, Sanquin-Leiden University Medical Center, The Netherlands j.j.zwaginga@lumc.nl.
Bronno van der HoltHOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam.
Peter A Te BoekhorstDept. of Hematology, Erasmus MC, Rotterdam.
Bart J BiemondDept. of Hematology, Academic Medical Center Amsterdam, The Netherlands.
Mark-David LevinDept. of Internal Medicine, Albert Schweitzer Hospital, Dordrecht.
René van der GriendDepartment of Internal Medicine, Diakonessenhuis, Utrecht.
Anneke BrandDept. of Immunohematology and Blood Transfusion, Leiden University Medical Center and the Jon J van Rood Center for Clinical Transfusion Research, Sanquin-Leiden University Medical Center, The Netherlands.
Sonja ZweegmanDept. of Hematology, VU University Medical Center, Amsterdam.
Hans F M PruijtDept. of Internal Medicine, Jeroen Bosch Hospital, Den Bosch.
Vera M J NovotnyDept. of Hematology, Radboud University Medical Centre, Nijmegen.
Art VreugdenhilDept of Internal Medicine, Máxima Medical Center, Veldhoven.
Marco R de GrootDept. of Internal Medicine, Medisch Spectrum Twente, Enschede.
Okke de WeerdtDept. of Internal Medicine, St. Antonius Hospital, Nieuwegein.
Elisabeth C M van PampusDept. of Laboratory Medicine, Radboud University Medical Center, Nijmegen.
Tanja M van Maanen-LammeDept. of Internal Medicine, Westfriesgasthuis, Hoorn.
Shulamiet WittebolDept. of Internal Medicine, Meander Hospital, Amersfoort.
Martin R SchipperusDept. of Internal Medicine, HagaZiekenhuis, Den Haag.
Matthijs H SilbermannDept. of Internal Medicine, Tergooiziekenhuizen, Blaricum.
Peter C HuijgensDept. of Hematology, VU University Medical Center, Amsterdam.
Marleen LutenHOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam.
Rene HollesteinHOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam.
Jan A C BrakenhoffWaterland hospital, Purmerend.
Jolanda G SchramaDept. of Internal Medicine, Spaarne hospital, Hoofddorp.
Fransje A A ValsterDept. of Internal Medicine, Lievensberg Hospital, Bergen op Zoom, The Netherlands.
Gerjo A VeldersDept. of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands.
Harry R KoeneDept. of Internal Medicine, St. Antonius Hospital, Nieuwegein.
Dutch HOVON 64 study group
Radboud University Nijmegen · NLSt. Antonius Ziekenhuis · NLAcademic Medical Center · NLAlbert Schweitzer Hospital · GAAmsterdam UMC Location VUmc · NLDiakonessenhuis hospital · NLErasmus University Rotterdam · NLHaga Hospital · NLJeroen Bosch Ziekenhuis · NLJon J van Rood Centre for Clinical Transfusion Research · NLMeander Medisch Centrum · NLMedisch Spectrum Twente · NLSpaarne Ziekenhuis · NLTergooi · NLUniversity Medical Center · USWaterlandziekenhuis · NLWestfriesgasthuis · NLZiekenhuis Gelderse Vallei · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAntibodies, Monoclonal, Murine-DerivedDrug Administration ScheduleDrug Dosage CalculationsFemaleHumansImmunologic FactorsMaleMiddle AgedPurpura, Thrombocytopenic, IdiopathicRecurrenceRituximabSurvival AnalysisTreatment OutcomeAntibodies, Monoclonal, Murine-DerivedImmunologic FactorsRituximabearly responseimmune thrombocytopeniaopen label phase IIrituximabsplenectomy delaying

Identifiers

PMID25425692
PMCPMC4349285
OpenAlexW2059727530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.